Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy

CONCLUSIONS: Interventions affecting the nitric oxide pathway probably do not seem to influence all-cause (fetal and neonatal) mortality in pregnant women carrying a baby with FGR, although more evidence is needed. The certainty of this evidence is moderate for sildenafil and low for tadalafil and nitroglycerin. For sildenafil a fair amount of data are available from randomised clinical trials, but with low numbers of participants. Therefore, the certainty of evidence is moderate. For the other interventions investigated in this review there are insufficient data, meaning we do not know whether these interventions improve perinatal and maternal outcomes in pregnant women with FGR.PMID:37428872 | PMC:PMC10332237 | DOI:10.1002/14651858.CD014498

Source: Cochrane Database of Systematic Reviews - July 10, 2023 Category: General Medicine Authors: Anouk Pels Wessel Ganzevoort Louise C Kenny Philip N Baker Peter von Dadelszen Christian Gluud Chirag T Kariya Aleid G Leemhuis Katie M Groom Andrew N Sharp Laura A Magee Janus C Jakobsen Ben Willem J Mol Aris T Papageorghiou Source Type: research